Brilinta Boost For AZ In Stroke Study
Outperforms Aspirin Alone In 11,000-Patient Trial
You may also be interested in...
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
AstraZeneca PLC’s newer oncology treatments are currently powering its growth, but the company is also looking to its cardiovascular, renal & metabolism (CVRM) portfolio to contribute, and a new study of Brilinta will help.
AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.